Celularity (CELU) Competitors $2.30 +0.10 (+4.55%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends CELU vs. IKT, CYBN, CGEN, CRDF, ACRS, SLN, SCPH, ALEC, LYEL, and GNFTShould you be buying Celularity stock or one of its competitors? The main competitors of Celularity include Inhibikase Therapeutics (IKT), Cybin (CYBN), Compugen (CGEN), Cardiff Oncology (CRDF), Aclaris Therapeutics (ACRS), Silence Therapeutics (SLN), scPharmaceuticals (SCPH), Alector (ALEC), Lyell Immunopharma (LYEL), and Genfit (GNFT). These companies are all part of the "pharmaceutical products" industry. Celularity vs. Inhibikase Therapeutics Cybin Compugen Cardiff Oncology Aclaris Therapeutics Silence Therapeutics scPharmaceuticals Alector Lyell Immunopharma Genfit Celularity (NASDAQ:CELU) and Inhibikase Therapeutics (NYSE:IKT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, community ranking, media sentiment, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends. Which has more volatility and risk, CELU or IKT? Celularity has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500. Comparatively, Inhibikase Therapeutics has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500. Does the media favor CELU or IKT? In the previous week, Inhibikase Therapeutics' average media sentiment score of 0.00 beat Celularity's score of -1.00 indicating that Inhibikase Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Celularity Negative Inhibikase Therapeutics Neutral Which has higher valuation & earnings, CELU or IKT? Inhibikase Therapeutics has lower revenue, but higher earnings than Celularity. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCelularity$22.77M2.22-$196.29MN/AN/AInhibikase Therapeutics$260K702.91-$19.03M-$2.67-1.02 Is CELU or IKT more profitable? Inhibikase Therapeutics has a net margin of 0.00% compared to Celularity's net margin of -72.72%. Celularity's return on equity of -119.53% beat Inhibikase Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Celularity-72.72% -119.53% -25.40% Inhibikase Therapeutics N/A -350.63%-201.82% Do analysts recommend CELU or IKT? Inhibikase Therapeutics has a consensus price target of $6.50, indicating a potential upside of 138.97%. Given Inhibikase Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Inhibikase Therapeutics is more favorable than Celularity.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Celularity 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Inhibikase Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders hold more shares of CELU or IKT? 19.0% of Celularity shares are held by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are held by institutional investors. 22.1% of Celularity shares are held by company insiders. Comparatively, 4.6% of Inhibikase Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the MarketBeat Community believe in CELU or IKT? Inhibikase Therapeutics received 1 more outperform votes than Celularity when rated by MarketBeat users. Likewise, 90.00% of users gave Inhibikase Therapeutics an outperform vote while only 42.11% of users gave Celularity an outperform vote. CompanyUnderperformOutperformCelularityOutperform Votes842.11% Underperform Votes1157.89% Inhibikase TherapeuticsOutperform Votes990.00% Underperform Votes110.00% SummaryInhibikase Therapeutics beats Celularity on 10 of the 15 factors compared between the two stocks. Get Celularity News Delivered to You Automatically Sign up to receive the latest news and ratings for CELU and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CELU vs. The Competition Export to ExcelMetricCelularityPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$50.58M$6.22B$5.21B$9.14BDividend YieldN/A2.94%5.13%4.02%P/E RatioN/A9.8789.3417.36Price / Sales2.22309.211,240.0477.11Price / Cash0.2961.4443.7535.97Price / Book1.096.055.314.79Net Income-$196.29M$154.90M$122.54M$225.00M7 Day Performance11.11%-0.32%0.59%2.62%1 Month Performance-1.29%0.43%2.55%3.81%1 Year Performance-21.77%3.08%25.29%20.10% Celularity Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CELUCelularity0.4894 of 5 stars$2.30+4.5%N/A-21.8%$50.58M$22.77M0.00220Short Interest ↑Negative NewsGap DownIKTInhibikase Therapeutics1.6593 of 5 stars$2.66-9.8%$6.50+144.4%+58.1%$178.73M$260,000.00-1.006Positive NewsGap DownCYBNCybin2.9391 of 5 stars$8.90+0.1%$138.00+1,450.6%N/A$177.93MN/A-1.3450Positive NewsCGENCompugen2.4353 of 5 stars$1.99+21.3%$4.00+101.0%+16.0%$177.58M$59.85M99.5070Positive NewsHigh Trading VolumeCRDFCardiff Oncology2.1519 of 5 stars$3.47-3.9%$10.33+197.8%+128.5%$177.44M$688,000.00-3.6920Positive NewsACRSAclaris Therapeutics4.0051 of 5 stars$2.48+0.4%$11.00+343.5%+125.4%$177.15M$27.08M-4.7786Short Interest ↑Positive NewsHigh Trading VolumeSLNSilence Therapeutics2.1072 of 5 stars$5.90-1.5%$57.20+869.5%-72.2%$176.58M$16.25M-3.76100SCPHscPharmaceuticals3.335 of 5 stars$3.51+3.2%$15.00+327.4%-38.6%$175.64M$30.28M-1.8530ALECAlector4.5046 of 5 stars$1.79-0.6%$3.75+109.5%-70.9%$175.30M$61.51M-1.05270Short Interest ↓LYELLyell Immunopharma2.2041 of 5 stars$0.59-1.7%$1.00+68.4%-69.7%$173.46M$63,000.00-0.75270GNFTGenfit1.646 of 5 stars$3.44-4.4%$13.00+277.9%+4.9%$171.99M$76.06M0.00120Short Interest ↑News CoveragePositive News Related Companies and Tools Related Companies IKT Competitors CYBN Competitors CGEN Competitors CRDF Competitors ACRS Competitors SLN Competitors SCPH Competitors ALEC Competitors LYEL Competitors GNFT Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CELU) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredTrump’s Inauguration Shocker: “Move Your Cash Now”Just in the first week after Trump's win, many stocks jumped by double and even triple digits. But now he's...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celularity Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Celularity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CELU Stock Alerts